{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T22:33:41Z","timestamp":1781562821614,"version":"3.54.5"},"reference-count":18,"publisher":"National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)","issue":"4","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp. oncol."],"abstract":"<jats:p>Background. Age-specific biological differences in breast cancer (BC) shape the disease course, therapeutic sensitivity, and prognosis. The microRNAs hsa-miR-26b-5p and hsa-miR-186-5p are considered promising biomarkers of tumor aggressiveness and treatment response, yet their age-dependent expression features remain insufficiently characterized. Aim. To evaluate age-related expression patterns of hsa-miR-26b-5p and hsa-miR-186-5p in the BC tissue samples and their relation to the response to neoadjuvant 4AC chemotherapy. Materials and Methods. Expression levels of hsa-miR- 26b-5p and hsa-miR-186-5p were analyzed by qRT-PCR in formalin-fixed paraffin-embedded tissue samples of BC patients (n = 56) divided into two age groups: \u226445 and &gt;45 years. MiRNAs expression patterns were analyzed in relation to molecular BC subtype, disease stage, T and N categories by TNM, and treatment response grades assessed by the Miller \u2014 Payne system. Results. Patients \u226445 years exhibited significantly higher miR-26b-5p levels (1.78-fold; p = 0.0005), especially in the luminal B subtype tumors (7.26\u20148.45-fold). The reduced miR-26b-5p and miR-186-5p levels in younger patients were associated with a locoregionally advanced disease (stage III) and lymph-node metastasis. In patients \u226545 years, miR-186-5p levels were significantly higher in the HER2\/neu-positive subtype (2.9-fold; p = 0.0278) and in the younger patients responding to 4AC NACT compared to the older responders. Conclusions. In BC, hsa-miR-26b-5p and hsa-miR-186-5p exhibited pronounced age-specific regulatory patterns and could be considered potential markers of BC course and efficacy of anthracycline-based therapy.<\/jats:p>","DOI":"10.15407\/exp-oncology.2025.04.459","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:19:58Z","timestamp":1772788798000},"page":"459-466","source":"Crossref","is-referenced-by-count":1,"title":["ROLE OF miR-26b-5p AND miR-186-5p IN BREAST CANCER PATIENTS OF YOUNG AGE: CLINICAL ASSOCIATIONS AND RELATION TO ANTHRACYCLINE RESPONSE"],"prefix":"10.15407","volume":"47","author":[{"given":"\u041e.","family":"Martyniuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Mushii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Chekhun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"32237","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249.","journal-title":"CA Cancer J Clin"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Shang R, Lee S, Senavirathne G, Lai EC. MicroRNAs in action: biogenesis, function and regulation. Nat Rev Genet. 2023;24(12):816-833. https:\/\/doi.org\/10.1038\/s41576-023-00611-y","DOI":"10.1038\/s41576-023-00611-y"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Sandau US, Wiedrick JT, McFarland TJ, et al. Analysis of the longitudinal stability of human plasma miRNAs and implications for disease biomarkers. Sci Rep. 2024;14:2148. https:\/\/doi.org\/10.1038\/s41598-024-52681-5","DOI":"10.1038\/s41598-024-52681-5"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Lukianova N, Zadvornyi T, Kashuba E, et al. Expression of markers of bone tissue remodeling in breast cancer and prostate cancer cells in vitro. Exp Oncol. 2022;44(1):39-46. https:\/\/doi.org\/10.32471\/exp-oncology.2312-8852.vol- 44-no-1.17354","DOI":"10.32471\/exp-oncology.2312-8852.vol-44-no-1.17354"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Zadvornyi T, Lukianova N, Borikun T, et al. Mast cells as a tumor microenvironment factor associated with the ag- gressiveness of prostate cancer. Neoplasma. 2022;69(6):1490-1498. https:\/\/doi.org\/10.4149\/neo_2022_221014N1020","DOI":"10.4149\/neo_2022_221014N1020"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Chekhun V, Borikun T, Mushii O, et al. Expression profile of miR-145, -182, -21, -27a, -29b, and -34a in breast cancer patients of young age. Exp Oncol. 2023;45(4):421-431. https:\/\/doi.org\/10.15407\/exp-oncology.2023.04.421","DOI":"10.15407\/exp-oncology.2023.04.421"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Borikun T, Mushii O, Pavlova A, et al. Tumor microenvironment-associated miR-7-5p, miR-19a-3p, and miR- 23b-3p expression in prostate cancer with different progression risk. Exp Oncol. 2023;45(4):432-442. https:\/\/doi. org\/10.15407\/exp-oncology.2023.04.432","DOI":"10.15407\/exp-oncology.2023.04.432"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Mushii O, Pavlova A, Bazas V, et al. Mast cells as a factor in regulation of breast cancer stromal component asso- ciated with breast cancer aggressiveness. Exp Oncol. 2024;46(4):311-323. https:\/\/doi.org\/10.15407\/exp-oncology. 2024.04.311","DOI":"10.15407\/exp-oncology"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Chekhun V, Martynyuk O, Lukianova Y, et al. Features of breast cancer in patients of young age: search for di- agnosis optimization and personalized treatment. Exp Oncol. 2023;45(2):139-150. https:\/\/doi.org\/10.15407\/exp- oncology.2023.02.139","DOI":"10.15407\/exp-oncology.2023.02.139"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Fukumoto I, Kikkawa N, Matsushita R, et al. Tumor-suppressive microRNAs (miR-26a\/b, miR-29a\/b\/c and miR-218) concertedly suppressed metastasis-promoting LOXL2 in head and neck squamous cell carcinoma. J Hum Genet. 2016;61(2):109-118. https:\/\/doi.org\/10.1038\/jhg.2015.120","DOI":"10.1038\/jhg.2015.120"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Lu Q, Chen W, Ji Y, et al. Ursolic acid enhances cytotoxicity of doxorubicin-resistant triple-negative breast cancer cells via ZEB1-AS1\/miR-186-5p\/ABCC1 axis. Cancer Biother Radiopharm. 2021;37:673. https:\/\/doi.org\/10.1089\/ cbr.2020.4147","DOI":"10.1089\/cbr.2020.4147"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Ma S, Wei H, Wang C, Han J, Chen X, Li Y. miR-26b-5p inhibits cell proliferation and EMT by targeting MYCBP in triple-negative breast cancer. Cell Mol Biol Lett. 2021;26(1):52. https:\/\/doi.org\/10.1186\/s11658-021-00288-3","DOI":"10.1186\/s11658-021-00288-3"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Lnc00462717 regulates the permeability of the blood-brain tumor barrier through interaction with PTBP1 to inhibit the miR-186-5p\/Occludin signaling pathway. FASEB J. 2020;34(8):9941-9958. https:\/\/doi.org\/10.1096\/ fj.202000045R","DOI":"10.1096\/fj.202000045R"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747- 752. https:\/\/doi.org\/10.1038\/35021093","DOI":"10.1038\/35021093"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Ding Q, Wang Y, Zuo Z, et al. Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Hum Pathol. 2018;77:121-129. https:\/\/doi.org\/10.1016\/j.humpath.2018.04.002","DOI":"10.1016\/j.humpath.2018.04.002"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Zhou A, Pan H, Sun D, et al. miR-26b-5p inhibits proliferation, migration and invasion of human papillary thyroid cancer in a \uf062-catenin-dependent manner. Onco Targets Th r. 2020;13:1593-603. https:\/\/doi.org\/10.2147\/OTT.S236319","DOI":"10.2147\/OTT.S236319"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Wang Z, Zhou X, Deng X, et al. miR-186-ANXA9 signaling inhibits tumorigenesis in breast cancer. Front Oncol. 2023;13:1166666. https:\/\/doi.org\/10.3389\/fonc.2023.1166666","DOI":"10.3389\/fonc.2023.1166666"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Tessitore A, Cicciarelli G, Del Vecchio F, et al. MicroRNAs in the DNA damage\/repair network and cancer. Int J Genomics. 2014;2014:820248. https:\/\/doi.org\/10.1155\/2014\/820248","DOI":"10.1155\/2014\/820248"}],"container-title":["Experimental Oncology"],"original-title":[],"link":[{"URL":"https:\/\/exp-oncology.com.ua\/index.php\/Exp\/article\/download\/578\/450","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/exp-oncology.com.ua\/index.php\/Exp\/article\/download\/578\/450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:27:49Z","timestamp":1772789269000},"score":1,"resource":{"primary":{"URL":"https:\/\/exp-oncology.com.ua\/index.php\/Exp\/article\/view\/578"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,3,5]]}},"URL":"https:\/\/doi.org\/10.15407\/exp-oncology.2025.04.459","relation":{},"ISSN":["2312-8852","1812-9269"],"issn-type":[{"value":"2312-8852","type":"electronic"},{"value":"1812-9269","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,5]]}}}